Biofrontera Inc.'s Leslie Hopkins Named PM360 Trailblazer 2022 Brand Champion for DermatologyGlobeNewsWire • 08/18/22
Biofrontera Inc.'s (BFRI) CEO Erica Monaco on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/12/22
Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/12/22
Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbHGlobeNewsWire • 08/01/22
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private PlacementGlobeNewsWire • 07/27/22
Biofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing ExcellenceGlobeNewsWire • 06/09/22
Biofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 ConferenceGlobeNewsWire • 05/31/22
New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera's Ameluz®GlobeNewsWire • 05/24/22
Biofrontera, Inc. (BFRI) CEO Erica Monaco on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/13/22
Biofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser EducationGlobeNewsWire • 05/05/22
Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®GlobeNewsWire • 04/13/22
Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stocks Are Soaring FridayInvestorPlace • 04/08/22
Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business UpdateGlobeNewsWire • 04/08/22
Biofrontera Inc. Announces Preliminary Product Revenues for the First Quarter of 2022GlobeNewsWire • 04/06/22
Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022GlobeNewsWire • 04/01/22
Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of Dermatology Annual MeetingGlobeNewsWire • 03/17/22
Biofrontera Inc. Announces FDA Orange Book Listing of U.S. Patent for BF-RhodoLED® XL, Extends Protection of Ameluz®-PDT Through October 2040GlobeNewsWire • 03/14/22